ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.
ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.
ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.
|Apr 24, 2019||ENDRA Life Sciences to Host First Quarter 2019 Results Conference Call on Tuesday, May 14, 2019 at 4:30 p.m. ET|
|Apr 17, 2019||ENDRA Life Sciences Granted U.S. Patent for Determining Fractional Fat Content of Tissue|
|Apr 03, 2019||ENDRA Life Sciences Receives ISO 13485 Certification|
|Mar 29, 2019||ENDRA Life Sciences Reports Initial Findings on First Human TAEUS Feasibility Study of Liver Fat|
|Mar 11, 2019||ENDRA Life Sciences Reports Full Year 2018 Financial & Operational Results|
|Day Range||1.48 - 1.58|
|52 Week Range||1.36 - 5.75|
|Bid/Ask||1.50 / 1.57|
|Bid/Ask Size||500 X 300|
|Market Cap||11.36 million|
|Shares Outstanding||7.42 million|
|Dividend/Yield||0.00 / 0.00%|
|P/E Ratio (TTM)||N/A|